Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Main subject
Publication year range
1.
Front Psychiatry ; 15: 1274192, 2024.
Article in English | MEDLINE | ID: mdl-38328761

ABSTRACT

Introduction: Mental health disorders (MHDs) are responsible for much impairment of quality of life in Brazil and worldwide. Early diagnosis and effective treatment strategies are required due to the heterogeneous symptoms and multifactorial etiology. Methods: A descriptive retrospective observational study was performed aiming to characterize the clinical and psychiatric profiles of patients with MHD attending a Brazilian public tertiary psychiatric outpatient clinic, which is a reference health service for more than 2 million inhabitants. Predominant clinical and sociodemographic aspects of patients were evaluated between March 2019 and March 2021. Results: A total of 8,384 appointments were analyzed. The majority of patients were female, and the mean age was 45 years old. Generalized anxiety disorder (GAD) was the most common MHD. The prevailing symptoms were sadness, anxiety, and irritability, with the most prescribed medications being selective serotonin reuptake inhibitors. Conclusion: The epidemiological characterization of mental disorders in specialized mental health outpatient clinics provides evidence for the establishment of more specific protocols and advocates a dimensional transdiagnostic approach as an aid to public mental health services.

2.
Trends Psychiatry Psychother ; 43(4): 278-285, 2021.
Article in English | MEDLINE | ID: mdl-34982515

ABSTRACT

INTRODUCTION: Schizophrenia is a complex psychiatric disorder that affects approximately twenty million people worldwide. Various factors have been associated with the physiopathology of this disease such as oxidative stress, which is an imbalance between pro-oxidant and antioxidant molecules. OBJECTIVE: This study evaluated the association between biomarkers of oxidative stress and response to pharmacological treatment among patients with schizophrenia in the context of their clinical information, demographic data, and lifestyle. METHODS: A total of 89 subjects were included, 26 of whom were treatment-responsive schizophrenia patients (Group 1), 27 treatment-resistant schizophrenia patients (Group 2), and 36 healthy controls (Group 3). All of the subjects completed a questionnaire to provide clinical and demographic data, and all provided peripheral blood samples. The oxidative stress markers analyzed using spectrophotometry were catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), total glutathione (GSH-t), malondialdehyde (MDA), and Trolox-equivalent antioxidant capacity (TEAC; p < 0.05). RESULTS: When all schizophrenia patients (G1 + G2) were compared to the control group, SOD levels were found to be lower among schizophrenia patients (p < 0.0001), while MDA and CAT levels were higher (p < 0.0001 and p = 0.0191, respectively). GPx, GSH-t, and TEAC levels were similar in all three groups (p > 0.05). CONCLUSION: Lower SOD levels and higher MDA and CAT levels indicate oxidative damage in schizophrenia patients, regardless of their response to pharmacological treatment. Smoking is associated with oxidative stress, in addition, a family history of the disease was also found to be correlated with cases of schizophrenia, which reflects the relevance of genetics in disease development.


Subject(s)
Schizophrenia , Biomarkers , Glutathione Peroxidase/metabolism , Humans , Oxidative Stress , Schizophrenia/drug therapy , Schizophrenia, Treatment-Resistant
3.
J. bras. psiquiatr ; 63(3): 185-190, July-Sept/2014. tab, graf
Article in Portuguese | LILACS | ID: lil-728791

ABSTRACT

Objetivos A esquizofrenia está associada a alto grau de incapacidade e importantes déficits neuropsicológicos, sociais e vocacionais. Pesquisas têm sido realizadas com o objetivo de identificar fatores preditivos para refratariedade, a fim de melhorar o tratamento e a qualidade de vida do paciente com esquizofrenia. O presente estudo teve o objetivo de verificar a frequência de pacientes com esquizofrenia refratária acompanhados em serviço terciário, estabelecer o perfil clínico e sociodemográfico e analisar possíveis fatores associados à refratariedade clínica. Métodos Sessenta e oito pacientes com esquizofrenia foram incluídos no estudo, sendo 36 refratários ao tratamento (52,9%). Os dados clínicos e sociodemográficos de ambos os grupos foram coletados, analisados e comparados. Um modelo de regressão logística foi elaborado com o objetivo de analisar possíveis fatores associados à refratariedade clínica. Resultados Entre o grupo refratário, houve maior frequência do sexo masculino (p = 0,03), número de antipsicóticos em uso (p < 0,01), internações ao longo da vida (p < 0,01) e de polifarmácia (p < 0,01). Escolaridade, estado civil, história familiar de esquizofrenia e uso de substâncias não foram confirmados como associados à refratariedade. Observou-se atraso temporal entre o estabelecimento da refratariedade clínica e a introdução da clozapina, indicado como o melhor antipsicótico para o tratamento de esquizofrenia refratária. Conclusão É importante e necessário o desenvolvimento de mais pesquisas a fim de investigar possíveis fatores clínicos e sociodemográficos preditores de refratariedade em pacientes com esquizofrenia, objetivando o início mais precoce de ações terapêuticas. .


Objectives Schizophrenia is associated with a high degree of disability and significant neuropsychological, social and vocational deficits. Studies have been undertaken to identify the predictive factors for refractoriness in order to improve the treatment and quality of life of such patients. The present study aimed to determine the frequency of patients with schizophrenia who are refractory and non-refractory treated in a tertiary center, the clinical and sociodemographic profile of such population and to analyze the associated factors of clinical refractoriness. Methods Sixty-eight patients with schizophrenia were included, and 36 were refractory to treatment (52.9%). Clinical and sociodemographic data of both groups were collected, analyzed and compared. A logistic regression model was elaborated in order to verify possible associations with clinical refractoriness. Results The refractory group had a higher prevalence of males (p = 0.03), antipsychotic use (p < 0.01), hospitalizations during lifetime (p < 0.01) and polypharmacy (p < 0.01). Educational level, marital status, family history of schizophrenia and substance use, were not associated to refractoriness. A delay between the diagnostic of refractoriness and the initiation of clozapine, the best antipsychotic for the treatment of refractory schizophrenia, was also observed. Conclusion The importance of further research in disclosing possible clinical and socio-demographic predictors of refractoriness in schizophrenia is therefore necessary. .

SELECTION OF CITATIONS
SEARCH DETAIL
...